Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telmisartan + amlodipine + atorvastatin (Daewoong Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DWJ1578 is a fixed-dose combination (FDC) therapy developed by Daewoong Pharmaceutical for the treatment of patients with both hypertension and dyslipidemia. It consists of three active pharmaceutical ingredients: telmisartan, an angiotensin II receptor blocker (ARB); amlodipine, a calcium channel blocker (CCB); and atorvastatin, an HMG-CoA reductase inhibitor (statin). This triple combination aims to improve patient compliance by reducing the pill burden for individuals requiring management of both blood pressure and cholesterol levels. The drug is formulated as a solid dosage form for oral administration and is currently in Phase 3 clinical trials in South Korea.
- Other names
- Telmisartan/Amlodipine/Atorvastatin
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)PPARG (Peroxisome proliferator-activated receptor gamma)AGTR1 (Angiotensin II Type-1 receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on telmisartan + amlodipine + atorvastatin (Daewoong Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telmisartan + amlodipine + atorvastatin (Daewoong Pharmaceutical).